KAN-NEURO-04

KAN-NEURO-04 is a preclinical small molecule drug discovery program being developed by Kantify in partnership with Istem and the Center for Neuroscience and Cell Biology (CECS). The program is focused on the treatment of neuromuscular disorders and utilizes Kantify's proprietary Sapian AI platform to identify and develop small molecules against multiple novel neurology targets. Currently in the hit discovery phase, the program aims to address therapeutic gaps in neuromuscular conditions where effective treatments are currently unavailable. The discovery process leverages AI to achieve a high target discovery rate and identify first-in-class therapeutic candidates.